Pregabalin versus placebo in postoperative pain relief of patients' status post photorefractive keratectomy: a double-masked, randomized, prospective study.

Purpose: Gabapentinoids are currently being used anecdotally for postoperative pain following photorefractive keratectomy (PRK) despite the lack of evidence. The purpose of this study is to evaluate the effectiveness of pregabalin in mitigating pain after PRK compared to the standard of care.

Methods: One hundred thirty-five patients scheduled for PRK at the Joint Warfighter Refractive Surgery Center in San Antonio, Texas were randomized to receive either oral pregabalin 75 mg twice daily for 5 days or placebo, in addition to the standard pain care regimen.

Insufficient stocking of cyanide antidotes in US hospitals that provide emergency care.

Objective: To identify the influence of catchment area, trauma center designation, hospital size, subspecialist employment, funding source, and other hospital characteristics on cyanide antidote stocking choice in US hospitals that provides emergency care.

Materials And Methods: A web-based survey was sent out to pharmacy managers through two listservs; the American Society of Health-Systems Pharmacists and the American College of Clinical Pharmacy. A medical marketing company also broadcasted the survey to 2,659 individuals.

The utility of the clinical pulmonary infection score.

The most common infectious complication in critically ill patients is ventilator-associated pneumonia. Ventilator-associated pneumonia has significant morbidity and mortality, prolongs mechanical ventilation, and extends length of hospitalization. Despite its prevalence and impact, uniform diagnostic standards are lacking.

Cyclosporin A disposition following acute traumatic brain injury.

Although the precise mechanism of action remains to be defined, Cyclosporin A (CsA) has demonstrated potential for neuroprotection in animal models. Predictive dosing strategies for CsA in acute traumatic brain injured (TBI) patients must account for the influence of the acute phase response on drug disposition. To characterize CsA pharmacokinetic parameters early following acute TBI, serial blood samples from patients enrolled into a Phase II dose-escalation trial were analyzed.